Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Zimmer Biomet Holdings is conducting the Persona IQ Cohort Study, a multicentric prospective cohort study aimed at evaluating the safety, functional performance, and effectiveness of the Persona IQ® Personalized Knee System integrated with the mymobility® Care Management Application. The study seeks to develop correlative measures to aid surgeons in managing patient recovery post-total knee arthroplasty by analyzing kinematic metrics captured through advanced sensors.
Intervention/Treatment: The intervention being tested is the Persona IQ, a device designed to alleviate pain and restore function in patients undergoing total knee arthroplasty. This system includes the mymobility® patient application, CTE Extension Implant, and the ZBEdgeTM Connected Artificial Intelligence data platform, which together facilitate remote therapeutic monitoring and data analysis.
Study Design: The study is observational with a cohort model and a prospective time perspective. It focuses on collecting data over time to assess the primary purpose of improving post-operative recovery management through advanced monitoring technologies.
Study Timeline: The study began on September 26, 2023, with its primary completion and estimated completion dates not yet disclosed. The latest update was submitted on August 14, 2025, indicating ongoing progress in the study’s execution.
Market Implications: This study update could positively influence Zimmer Biomet’s stock performance by showcasing innovation in orthopedic solutions and enhancing investor confidence. The integration of AI and remote monitoring in knee replacement systems positions Zimmer Biomet favorably against competitors, potentially driving market growth and attracting investor interest.
The Persona IQ Cohort Study is currently ongoing, with further details available on the ClinicalTrials portal.